SARS2-38 binds a conserved RBD epitope near the receptor-binding motif, enabling neutralization of variants carrying escape mutations that defeat other antibodies. Most neutralizing antibodies target mutable RBD or NTD regions, allowing variants to escape; SARS2-38's conserved epitope approach addresses this evolutionary pressure.
News-Medical.net
· Apr 29, 2021
· health
· 3 min de lectura
Medium
Verificación: Caracterizado
Researchers identify monoclonal antibody effective against SARS-CoV-2 variants
◉
Health & Medicine
8098 artículos relacionados
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% coincidencia
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% coincidencia
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% coincidencia
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% coincidencia
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% coincidencia
Cobertura Relacionada
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
US researchers develop broadly neutralizing monoclonal antibody (SARS2-38) effective against SARS-CoV-2 variants, offering potential therapeutic advancement in pandemic response.
Escalation Risk
low
Confidence
HIGH
United States
Global (pandemic-affected countries)
European Union
Asia-Pacific
Scientific advancement in US biomedical research strengthens American soft power and pharmaceutical leadership. Potential therapeutic monopoly if patented and commercialized could shift global health dependency dynamics, particularly affecting lower-income nations' access to treatments.
Similar to polio vaccine development (1950s) where US scientific breakthroughs established global health influence and shaped international medical policy frameworks.
Lente Económico
📈
Discovery of broadly neutralizing monoclonal antibody (SARS2-38) effective against SARS-CoV-2 variants could expand therapeutic options, supporting biotech/pharma growth and reducing pandemic-related economic disruptions.
Market Signal
bullish
Confidence
MED
Biotechnology/Pharmaceuticals
Healthcare/Medical devices
Diagnostics
Hospital/Clinical services
Vaccine development
Consumers gain access to additional treatment options for COVID-19 variants, potentially reducing hospitalization rates, mortality, and healthcare costs. May lower out-of-pocket medical expenses and reduce lost productivity from illness.
Likely to accelerate FDA review pathways for monoclonal antibody therapeutics; may influence public health strategies to balance vaccines and treatments; could affect government procurement budgets for pandemic response; may inform future pandemic preparedness frameworks.